Current HIV/AIDS Reports

, Volume 2, Issue 4, pp 177–183 | Cite as

The population effectiveness of highly active antiretroviral therapy: Are good drugs good enough?

  • Thomas P. Giordano
  • Maria E. Suarez-Almazor
  • Richard M. Grimes


Despite the success of highly active antiretroviral therapy (HAART) at reducing mortality from HIV infection, there is evidence that it is not reaching the all of the population that needs it, even in the developed world. To be maximally effective at the population level, all persons with HIV infection must be diagnosed; those persons with an indication for HAART must enter care, must receive HAART, and then must adhere to appointments and, finally, HAART itself. There is considerable evidence that significant portions of the population infected with HIV have not completed all of these steps of HIV care even in the developed world. Although new medications to treat HIV are certainly needed, significant improvements in viral, immunologic, and clinical outcomes could be achieved from improving timely diagnosis, access to HAART, and adherence to appointments, as well as adherence to HAART.


Human Immunodeficiency Virus Human Immunodeficiency Virus Infection Human Immunodeficiency Virus Testing Undetectable Viral Load Human Immunodeficiency Virus Care 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Wood E, Montaner JS, Bangsberg DR, et al.: Expanding access to HIV antiretroviral therapy among marginalized populations in the developed world. AIDS 2003, 17:2419–2427.PubMedCrossRefGoogle Scholar
  2. 2.
    Munoz A, Gange SJ, Jacobson LP: Distinguishing efficacy, individual effectiveness and population effectiveness of therapies. AIDS 2000, 14:754–756.PubMedCrossRefGoogle Scholar
  3. 3.
    Teshale E, Kamimoto L, Harris N, et al.: Estimated number of HIV-infected persons eligible for and receiving HIV antiretroviral therapy, 2003—United States [abstract 167]. Paper presented at the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 22–25, 2005.Google Scholar
  4. 4.
    Janssen RS, Holtgrave DR, Valdiserri RO, et al.: The serostatus approach to fighting the HIV epidemic: Prevention strategies for infected individuals. Am J Public Health 2001, 91:1019–1024.PubMedGoogle Scholar
  5. 5.
    Recsky MA, Brumme ZL, Chan KJ, et al.: Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy. J Infect Dis 2004, 190:285–292.PubMedCrossRefGoogle Scholar
  6. 6.
    Jain MK, Skiest DJ, Cloud JW, et al.: Changes in mortality related to human immunodeficiency virus infection: comparative analysis of inpatient deaths in 1995 and in 1999–2000. Clin Infect Dis 2003, 36:1030–1038.PubMedCrossRefGoogle Scholar
  7. 7.
    McNaghten AD, Hanson D, Kellerman S, et al.: Factors associated with immunologic stage at which patients initiate antiretroviral therapy [abstract 473-M]. Paper presented at the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA; February 24–28, 2002.Google Scholar
  8. 8.
    Egger M, May M, Chene G, et al.: Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002, 360:119–129.PubMedCrossRefGoogle Scholar
  9. 9.
    Blair JM, Fleming PL, Karon JM: Trends in AIDS incidence and survival among racial/ethnic minority men who have sex with men, United States, 1990–1999. J Acquir Immune Defic Syndr 2002, 31:339–347.PubMedGoogle Scholar
  10. 10.
    McGinnis KA, Fine MJ, Sharma RK, et al.: Understanding racial disparities in HIV using data from the veterans aging cohort 3-site study and VA administrative data. Am J Public Health 2003, 93:1728–1733.PubMedGoogle Scholar
  11. 11.
    Inungu JN: Potential barriers to seeking human immunodeficiency virus testing among adults in the United States: data from the 1998 National Health Interview Survey. AIDS Patient Care STDS 2002, 16:293–299.PubMedCrossRefGoogle Scholar
  12. 12.
    Number of persons tested for HIV—United States, 2002. MMWR Morb Mortal Wkly Rep 2004, 53:1110–1113.Google Scholar
  13. 13.
    Erbelding EJ, Chung S, Zenilman JM: Following-up for HIV test results: what limits return in an STD clinic population? Int J STD AIDS 2004, 15:29–32.PubMedCrossRefGoogle Scholar
  14. 14.
    Centers for Disease Control and Prevention: Advancing HIV prevention: new strategies for a changing epidemic—United States, 2003. MMWR Morb Mortal Wkly Rep 2003, 52:329–332.Google Scholar
  15. 15.
    Centers for Disease Control and Prevention: Cases of HIV infection and AIDS in the United States, by race/ethnicity, 1998–2002. HIV AIDS Surveill Suppl Rep 2004, 10.Google Scholar
  16. 16.
    Late versus early testing of HIV—16 Sites, United States, 2000–2003. MMWR Morb Mortal Wkly Rep 2003, 52:581–586.Google Scholar
  17. 17.
    Dybul M, Bolan R, Condoluci D, et al.: Evaluation of initial CD4+ T cell counts in individuals with newly diagnosed human immunodeficiency virus infection, by sex and race, in urban settings. J Infect Dis 2002, 185:1818–1821.PubMedCrossRefGoogle Scholar
  18. 18.
    Morgenstern TT, Grimes DE, Grimes RM: Assessment of readiness to initiate antiretroviral therapy. HIV Clin Trials 2002, 3:168–172.PubMedCrossRefGoogle Scholar
  19. 19.
    Turner BJ, Cunningham WE, Duan N, et al.: Delayed medical care after diagnosis in a US national probability sample of persons infected with human immunodeficiency virus. Arch Intern Med 2000, 160:2614–2622.PubMedCrossRefGoogle Scholar
  20. 20.
    GardnerLI, Metsch LR, Anderson-Mahoney P, et al.: Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. AIDS 2005, 19:423–431. This randomized, controlled clinical trial demonstrated that case management for 90 days after diagnosis-improved linkage to and retention in HIV care.PubMedCrossRefGoogle Scholar
  21. 21.
    Palacio H, Li X, Wilson TE, et al.: Healthcare use by varied highly active antiretroviral therapy (HAART) strata: HAART use, discontinuation, and naivety. AIDS 2004, 18:621–630.PubMedCrossRefGoogle Scholar
  22. 22.
    Wood E, Hogg RS, Yip B, et al.: Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy? AIDS 2003, 17:711–720.PubMedCrossRefGoogle Scholar
  23. 23.
    Chene G, Sterne JA, May M, et al.: Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003, 362:679–686.PubMedCrossRefGoogle Scholar
  24. 24.
    DHHS Panel on Clinical Practices for Treatment of HIV Infection: Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Accessed May 9, 2005.Google Scholar
  25. 25.
    Cohen MH, Cook JA, Grey D, et al.: Medically eligible women who do not use HAART: the importance of abuse, drug use, and race. Am J Public Health 2004, 94:1147–1151.PubMedCrossRefGoogle Scholar
  26. 26.
    Cunningham WE, Markson LE, Andersen RM, et al.: Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the United States. HCSUS Consortium. HIV Cost and Services Utilization. J Acquir ImmuneDefic Syndr 2000, 25:115–123.CrossRefGoogle Scholar
  27. 27.
    Giordano TP, White AC, Jr., Sajja P, et al.: Factors associated with the use of highly active antiretroviral therapy in patients newly entering care in an urban clinic. J Acquir Immune Defic Syndr 2003, 32:399–405.PubMedCrossRefGoogle Scholar
  28. 28.
    Wood E, Montaner JS, Tyndall MW, et al.: Prevalence and correlates of untreated human immunodeficiency virus type 1 infection among persons who have died in the era of modern antiretroviral therapy. J Infect Dis 2003, 188:1164–1170.PubMedCrossRefGoogle Scholar
  29. 29.
    Smedley BD, Stith AY, Nelson AR, eds.: Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, D.C.: National Academy Press; 2003Google Scholar
  30. 30.
    Celentano DD, Galai N, Sethi AK, et al.: Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS 2001, 15:1707–1715.PubMedCrossRefGoogle Scholar
  31. 31.
    Lucas GM, Chaisson RE, Moore RD: Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999, 131:81–87.PubMedGoogle Scholar
  32. 32.
    Sethi AK, Celentano DD, Gange SJ, et al.: Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 2003, 37:1112–1118.PubMedCrossRefGoogle Scholar
  33. 33.
    Valdez H, Lederman MM, Woolley I, et al.: Human immunodeficiency virus 1 protease inhibitors in clinical practice: predictors of virological outcome. Arch Intern Med 1999, 159:1771–1776.PubMedCrossRefGoogle Scholar
  34. 34.
    Centers for Disease Control and Prevention: Recommendations for incorporating human immunodeficiency virus (HIV) prevention into the medical care of persons living with HIV. Clin Infect Dis 2004, 38:104–121.CrossRefGoogle Scholar
  35. 35.
    Giordano TP, Visnegarwala F, White AC Jr, et al.: Patients referred to an urban HIV clinic frequently fail to establish care: Factors predicting failure. AIDS Care 2005, 17:773–783.PubMedCrossRefGoogle Scholar
  36. 36.
    Paterson DL, Swindells S, Mohr J, et al.: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000, 133:21–30.PubMedGoogle Scholar
  37. 37.
    Maher K, Klimas N, Fletcher MA, et al.: Disease progression, adherence, and response to protease inhibitor therapy for HIV infection in an urban Veterans Affairs medical center. J Acquir Immune Defic Syndr 1999, 22:358–363.PubMedGoogle Scholar
  38. 38.
    Bangsberg DR, Hecht FM, Charlebois ED, et al.: Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000, 14:357–366.PubMedCrossRefGoogle Scholar
  39. 39.
    Bangsberg DR, Perry S, Charlebois ED, et al.: Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001, 15:1181–1183.PubMedCrossRefGoogle Scholar
  40. 40.
    Hogg RS, Heath K, Bangsberg D, et al.: Intermittent use of triple -combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 2002, 16:1051–1058.PubMedCrossRefGoogle Scholar
  41. 41.
    Stone VE, Hogan JW, Schuman P, et al.: Antiretroviral regimen complexity, self-reported adherence, and HIV patients’ understanding of their regimens: survey of women in the HER study. J Acquir Immune Defic Syndr 2001, 28:124–131.PubMedCrossRefGoogle Scholar
  42. 42.
    Gifford AL, Bormann JE, Shively MJ, et al.: Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr 2000, 23:386–395.PubMedGoogle Scholar
  43. 43.
    Howard AA, Arnsten JH, Lo Y, et al.: A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS 2002, 16:2175–2182.PubMedCrossRefGoogle Scholar
  44. 44.
    Wood E, Montaner JS, Yip B, et al.: Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ 2003, 169:656–661.PubMedGoogle Scholar
  45. 45.
    Visnegarwala F, Graviss EA, Sajja P, et al.: Determinants of sustained virological suppression in indigent, HIV-infected patients: is single protease inhibitor-based antiretroviral therapy truly highly active? HIV Clin Trials 2004, 5:117–124.PubMedCrossRefGoogle Scholar
  46. 46.
    Freedberg KA, Samet JH: Think HIV: why physicians should lower their threshold for HIV testing. Arch Intern Med 1999, 159:1994–2000.PubMedCrossRefGoogle Scholar
  47. 47.
    SandersGD, Bayoumi AM, Sundaram V, et al.: Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 2005, 352:570–585. This analysis shows that screening for HIV in the United States may be cost effective in a population with a prevalence of unidentified HIV infection as low as 0.05%.PubMedCrossRefGoogle Scholar
  48. 48.
    Paltiel AD, Weinstein MC, Kimmel AD, et al.: Expanded screening for HIV in the United States—an analysis of cost-effectiveness. N Engl J Med 2005, 352:586–595.PubMedCrossRefGoogle Scholar
  49. 49.
    WalenskyRP, Losina E, Malatesta L, et al.: Effective HIV case identification through routine HIV screening at urgent care centers in Massachusetts. Am J Public Health 2005, 95:71–73. The latest report from the "Think HIV" project, this paper reports on the effectiveness of an intervention to increase screening for HIV.PubMedCrossRefGoogle Scholar
  50. 50.
    Pilcher CD, Fiscus SA, Nguyen TQ, et al.: Detection of acute infections during HIV testing in North Carolina. N Engl J Med 2005, 352:1873–1883.PubMedCrossRefGoogle Scholar
  51. 51.
    Gross R, Bilker WB, Friedman HM, et al.: Provider inaccuracy in assessing adherence and outcomes with newly initiated antiretroviral therapy. AIDS 2002, 16:1835–1837.PubMedCrossRefGoogle Scholar
  52. 52.
    Bangsberg DR, Hecht FM, Clague H, et al.: Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr 2001, 26:435–442.PubMedGoogle Scholar
  53. 53.
    Macharia WM, Leon G, Rowe BH, et al.: An overview of interventions to improve compliance with appointment keeping for medical services. JAMA 1992, 267:1813–1817.PubMedCrossRefGoogle Scholar
  54. 54.
    Machtinger EL, Bangsberg D: Adherence to HIV antiretroviral therapy. HIV InSite Knowledge Base 2005. Accessed May 12, 2005.Google Scholar
  55. 55.
    Gulick RM, Ribaudo HJ, Shikuma CM, et al.: Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004, 350:1850–1861.PubMedCrossRefGoogle Scholar
  56. 56.
    Walmsley S, Bernstein B, King M, et al.: Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002, 346:2039–2046.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2005

Authors and Affiliations

  • Thomas P. Giordano
    • 1
  • Maria E. Suarez-Almazor
  • Richard M. Grimes
  1. 1.Houston Center for Quality of Care and Utilization StudiesMichael E. DeBakey VA Medical CenterHoustonUSA

Personalised recommendations